Reimbursement rate update for infliximab products Beginning April 1, 2020

February 26, 2020

Effective April 1, 2020, the following infliximab pharmaceutical products will be recategorized as group C products instead of multi-source products. This will affect the reimbursement rate on these medications.


Drug Name


REMICADE 100MG  Solution Reconstituted


INFLECTRA 100MG  Solution Reconstituted

If you have additional questions, email provider inquiries or call the Provider Contract Support Unit at 800-722-3730, Option 2.